Medtrum Highlights Real-World AID Experience at EDM HK 2026

Medtrum brought its diabetes technologies together with local clinical experience at Hong Kong’s annual endocrinology, diabetes and metabolism meeting

HONG KONG, October 28, 2026 /EINPresswire.com/ -- Medtrum joined healthcare professionals, partners and people living with diabetes at EDM HK 2026. The 9th Annual Meeting of Endocrinology, Diabetes & Metabolism Hong Kong was held on 24–25 October.

Over the two days, visitors came by the Medtrum booth to learn more about the company's continuous glucose monitoring (CGM), tubeless insulin pumps and automated insulin delivery (AID) systems, ask questions and discuss how these technologies could fit different patient needs. The conversations also gave Medtrum a chance to hear directly from doctors, nurses and others working in diabetes care in Hong Kong about what matters to them in day-to-day diabetes care.

One of the main highlights was a symposium where Dr. Chun-Yip Yeung brought a clinical perspective to the discussion. In his presentation, "Hybrid Closed-loop Insulin Pump: Case Sharing from an Endocrinologist with Limited Pump Experience," he drew on his own clinical experience and patient cases to look at how AID can work in everyday care.

Earlier in his career, Dr. Yeung had relatively limited exposure to insulin pumps. Few of his patients used them. More recently, however, he has seen the profile of patients requiring intensive insulin management become more varied, with more older adults developing insulin dependence later in life and often managing other medical conditions at the same time.

For some of these patients, the challenge is not only glucose control. Repeated injections, carbohydrate counting and a more demanding daily routine can add considerably to the burden of diabetes management. This changing clinical picture was part of what led Dr. Yeung to take a closer look at newer pump and AID technologies.

He described the Medtrum AID system as relatively straightforward to set up compared with his previous experience. In his practice, getting started involves teaching patients and caregivers how to use the pump, change the reservoir and set up the app, while the clinician enters individual treatment settings such as insulin requirements and glucose targets. Once these are in place, automated insulin delivery can be introduced as part of the patient's ongoing management.

The cases he shared also brought the discussion back to everyday life. In one example, a patient who had previously enjoyed going out for lunch with friends and family became reluctant to leave home after starting multiple daily injections. The experience illustrated how the burden of insulin treatment can extend well beyond glucose numbers.

Another patient Dr. Yeung discussed remained active after starting pump therapy and was able to continue playing golf. The case also showed the kind of small, practical adjustments that can come with using wearable diabetes technology in daily life.

In his conclusion, Dr. Yeung said advances in insulin pumps and CGM can improve glucose control, safety and quality of life. Based on his clinical experience, he also described Medtrum's tubeless AID system as effective, safe and affordable.

During the Q&A, an audience member asked about the support available after a patient starts using a closed-loop system. Dr. Yeung explained that patients receive individual follow-up through Medtrum's support network in Hong Kong, with dedicated communication channels available when needed. That kind of ongoing support matters alongside the technology itself, particularly when healthcare professionals and patients are getting used to a new way of managing insulin therapy.

Medtrum plans to keep the conversation going after EDM HK 2026, with further educational activities and workshops planned in Hong Kong. These will create more opportunities for healthcare professionals and the local diabetes community to explore diabetes technology in a practical setting.

About Medtrum
Medtrum is a global leader in diabetes technology, dedicated to making diabetes care smaller, simpler and smarter. Medtrum has developed the world’s smallest AID system, CGM and tubeless patch pump, with breakthrough miniaturization designed to make advanced diabetes technology remarkably discreet and comfortable to wear. At the core is our proprietary APGO^® advanced closed-loop artificial pancreas algorithm. Through a simple smartphone app, the system continuously analyzes real-time glucose data and automatically calculates and adjusts insulin delivery, dramatically reducing the need for manual intervention and simplifying everyday diabetes care — giving people with diabetes greater freedom in everyday life. Medtrum products are now available in more than 50 countries and regions and are covered by healthcare reimbursement systems in more than 20 European countries, including the UK, France, Germany, Italy, the Netherlands and the Nordic countries. Medtrum is advancing the next generation of diabetes care.

Jessie Cai
Medtrum Tech Limited
pr@medtrum.com.hk
Visit us on social media:
LinkedIn
X
Instagram
Facebook
YouTube
TikTok